AstraZeneca’s Farxiga succeeds in phase 3 trial in chronic kidney disease

This article was originally published here

In the DAPA-CKD trial that featured 4,304 adult patients, Farxiga 10mg, when compared to placebo, delivered a statistically significant and clinically meaningful impact on its primary endpoint of

The post AstraZeneca’s Farxiga succeeds in phase 3 trial in chronic kidney disease appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply